Neurocrine Biosciences, Inc (NASDAQ:NBIX) shares, rose in value on Friday, January 03, with the stock price up by 0.17% to the previous day’s close as strong demand from buyers drove the stock to $138.10.
Actively observing the price movement in the last trading, the stock closed the session at $137.86, falling within a range of $137.17 and $139.4. The value of beta (5-year monthly) was 0.353 whereas the PE ratio was 37.00 over 12-month period. Referring to stock’s 52-week performance, its high was $157.98, and the low was $110.95. On the whole, NBIX has fluctuated by 10.09% over the past month.
With the market capitalization of Neurocrine Biosciences, Inc currently standing at about $13.98 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NBIX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0.63, with the price of NBIX currently trading nearly 3.39% and 8.70% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 65.56, while the 7-day volatility ratio is showing 1.62% which for the 30-day chart, stands at 2.25%. Furthermore, Neurocrine Biosciences, Inc (NBIX)’s beta value is 0.32, and its average true range (ATR) is 3.05.
A comparison of Neurocrine Biosciences, Inc (NBIX) with its peers suggests the former has fared considerably weaker in the market. NBIX showed an intraday change of 0.17% in last session, and over the past year, it grew by 4.05%%.
Data on historical trading for Neurocrine Biosciences, Inc (NASDAQ:NBIX) indicates that the trading volumes over the past 10 days have averaged 1.08 and over the past 3 months, they’ve averaged 949.49K. According to company’s latest data on outstanding shares, there are 101.20 million shares outstanding.
Nearly 2.68% of Neurocrine Biosciences, Inc’s shares belong to company insiders and institutional investors own 91.86% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.39 million shares as on 2024-12-13, resulting in a short ratio of 3.86. According to the data, the short interest in Neurocrine Biosciences, Inc (NBIX) stood at 391.00 of shares outstanding as of 2024-12-13; the number of short shares registered in 2024-11-15 reached 4.24 million. The stock has risen by 1.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBIX stock heading into the next quarter.